{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:28:32Z","timestamp":1787390912138,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["arthroplastyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Arthroplasty"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.arth.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:07:43Z","timestamp":1781050063000},"page":"2688-2696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials"],"prefix":"10.1016","volume":"41","author":[{"given":"Chase W.","family":"Smitterberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Garvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Adolph V.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Vincent D.","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten M.","family":"Seyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arth.2026.06.008_bib1","article-title":"Projections and epidemiology of primary hip and knee arthroplasty in medicare patients to 2040-2060","volume":"8","author":"Shichman","year":"2023","journal-title":"JB JS Open Access"},{"key":"10.1016\/j.arth.2026.06.008_bib2","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.arth.2026.06.008_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45883","article-title":"Venous thromboembolism in total hip and total knee arthroplasty","volume":"6","author":"Simon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.arth.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1381612828666220418090928","article-title":"Prophylaxis for venous thromboembolic events in elective total hip and total knee arthroplasty","volume":"28","author":"Karasavvidis","year":"2022","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.arth.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2106\/JBJS.20.02250","article-title":"Venous thromboembolic prophylaxis after total hip and knee arthroplasty","volume":"103","author":"Lieberman","year":"2021","journal-title":"J Bone Joint Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-159-4-201308200-00008","article-title":"Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review","volume":"159","author":"Adam","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.arth.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2106\/JBJS.21.01529","article-title":"Recommendations from the ICM-VTE: hip & knee","volume":"104","year":"2022","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"Anderson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2026.06.008_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial","volume":"328","author":"Sidhu","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5435\/00124635-201112000-00008","article-title":"AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont","year":"2011","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2106\/JBJS.9408edit","article-title":"Preventing venous thromboembolic disease in patients undergoing elective total hip and knee arthroplasty","volume":"94","author":"Mont","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2026.06.008_bib12","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment","volume":"8","author":"L\u00f6wenberg","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arth.2026.06.008_bib13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.arth.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.arth.2026.06.008_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arth.2026.06.008_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1056\/NEJMe2414209","article-title":"Uncoupling thrombosis and hemostasis by inhibiting factor XI","volume":"392","author":"Angiolillo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arth.2026.06.008_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2026.06.008_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2026.06.008_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmed.2017.00019","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.arth.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.arth.2026.06.008_bib24","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014Systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arth.2026.06.008_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.arth.2026.06.008_bib28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"JACC"},{"key":"10.1016\/j.arth.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.arth.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.arth.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arth.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/ans.18284","article-title":"Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty","volume":"93","author":"Sidhu","year":"2023","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jama.2025.4486","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomized trials","volume":"334","author":"Chan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2026.06.008_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials","volume":"180","author":"Matharu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arth.2026.06.008_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ocl.2024.09.003","article-title":"Risk stratification for venous thromboembolism prophylaxis","volume":"56","author":"Mansour","year":"2025","journal-title":"Orthop Clin North Am"},{"key":"10.1016\/j.arth.2026.06.008_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0042-1742739","article-title":"Utilization of the caprini score for risk stratification of the arthroplasty patient in the prevention of postoperative venous thrombosis","volume":"48","author":"Krauss","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.arth.2026.06.008_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.arth.2026.06.008_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00402-014-2034-4","article-title":"High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline","volume":"134","author":"Leijtens","year":"2014","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib39","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.arth.2025.08.064","article-title":"Disruptive bleeding and comorbidity burden in total knee arthroplasty: associations with costs, lengths of stay, and readmissions","volume":"41","author":"Ng","year":"2026","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2026.06.008_bib40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jama.2019.12085","article-title":"Effect of low-intensity vs standard-intensity warfarin prophylaxis on venous thromboembolism or death among patients undergoing hip or knee arthroplasty: a randomized clinical trial","volume":"322","author":"Gage","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2026.06.008_bib41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2340\/17453674.2022.2207","article-title":"Low incidence of clinically relevant bleeding complications after fast-track arthroplasty: a register study of 8,511 arthroplasties","volume":"93","author":"Moisander","year":"2022","journal-title":"Acta Orthop"},{"key":"10.1016\/j.arth.2026.06.008_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040336","article-title":"Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study","volume":"11","author":"van der Veen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.arth.2026.06.008_bib43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5435\/00124635-201112000-00007","article-title":"Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont","year":"2011","journal-title":"Am Acad Orthop Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib44","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2026.06.008_bib45","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.thromres.2015.02.008","article-title":"Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: a meta-analysis of 6 randomized clinical trials","volume":"135","author":"Ma","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.arth.2026.06.008_bib46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clinthera.2012.12.005","article-title":"Rivaroxaban: an oral factor Xa inhibitor","volume":"35","author":"Thomas","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.arth.2026.06.008_bib47","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1016\/S2352-3026(24)00281-3","article-title":"Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants","volume":"11","author":"Ageno","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.arth.2026.06.008_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arth.2026.06.008_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/VHRM.S4441","article-title":"Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data","volume":"7","author":"Kwong","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.arth.2026.06.008_bib50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arth.2026.06.008_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2018.0374","article-title":"What surgeons should know about non\u2013vitamin K oral anticoagulants: a review","volume":"153","author":"Verma","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.arth.2026.06.008_bib52","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/ATVBAHA.114.303400","article-title":"Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty","volume":"35","author":"Messerschmidt","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arth.2026.06.008_bib53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2020.12.007","article-title":"Thromboprophylaxis for orthopedic surgery; an updated meta-analysis","volume":"199","author":"Haykal","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.arth.2026.06.008_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf4331","article-title":"Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis","volume":"8","author":"David","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.arth.2026.06.008_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.str.2017.12.010","article-title":"Structural basis for activity and specificity of an anticoagulant Anti-FXIa monoclonal antibody and a reversal agent","volume":"26","author":"Ely","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.arth.2026.06.008_bib56","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"}],"container-title":["The Journal of Arthroplasty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540326006078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540326006078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:21:24Z","timestamp":1787390484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883540326006078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0883540326006078"],"URL":"https:\/\/doi.org\/10.1016\/j.arth.2026.06.008","relation":{},"ISSN":["0883-5403"],"issn-type":[{"value":"0883-5403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Arthroplasty","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arth.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}